MK-677 (Ibutamoren) vs Sermorelin

Overview

MK-677 (Ibutamoren) and Sermorelin are both performance & growth peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares MK-677 (Ibutamoren) and Sermorelin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. MK-677 (Ibutamoren) is categorised under Performance & Growth, while Sermorelin falls under Performance & Growth. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. MK-677 (Ibutamoren): not FDA-approved; treated as a research compound. Sermorelin: not FDA-approved; treated as a research compound.

Dosing. MK-677 (Ibutamoren) is typically dosed at 10-25 mg (daily). Sermorelin is typically dosed at 200-500 mcg (daily before bed).

Can you stack them?

Some protocols combine peptides, but stacking MK-677 (Ibutamoren) and Sermorelin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between MK-677 (Ibutamoren) and Sermorelin?

MK-677 (Ibutamoren) and Sermorelin are both performance & growth peptides, but they differ in mechanism, dosing, and regulatory status. MK-677 (Ibutamoren) is not FDA-approved; generally classified as a research compound, whereas Sermorelin is not FDA-approved; generally classified as a research compound.

What is MK-677 (Ibutamoren) used for?

Oral GH secretagogue.

What is Sermorelin used for?

GHRH for natural GH release.

Can you take MK-677 (Ibutamoren) and Sermorelin together?

Some users combine peptides within a single protocol, but stacking MK-677 (Ibutamoren) and Sermorelin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is MK-677 (Ibutamoren) or Sermorelin FDA-approved?

MK-677 (Ibutamoren) is not FDA-approved; generally classified as a research compound. Sermorelin is not FDA-approved; generally classified as a research compound.